Bristol-Myers Squibb to present new data at EULAR 2014

Bristol-Myers Squibb has announced that it will be presenting new clinical data on a number of rheumatology innovations at the forthcoming European League Against Rheumatism (EULAR) annual meeting.

During the event in Paris from June 11th to 14th 2014, the company will present 20 abstracts on its pioneering T-cell co-stimulation modulator Orencia and investigational selective IL-6 cytokine inhibitor clazakizumab, both of which are therapies for rheumatoid arthritis (RA).

Results from the phase IIIb Avert study will highlight the induction of remission associated with Orencia in patients with highly-active early RA, while new data from the two-year head-to-head Ample trial, evaluating Orencia versus Humira in RA, will also be presented.

Additionally, 24-week efficacy, safety and MRI results from a phase IIb trial of clazakizumab will be showcased.

Michael Giordano, senior vice-president and head of development for oncology and immunoscience at Bristol-Myers Squibb, said: "Leveraging our heritage and expertise in immunoscience, Bristol-Myers Squibb remains focused on changing the course of immune-mediated diseases like RA."

The company also recently announced that it will be sharing data from its promising immuno-oncology portfolio at the forthcoming American Society of Clinical Oncology 2014 annual meeting.